Woodline Partners LP purchased a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 526,511 shares of the company's stock, valued at approximately $8,656,000. Woodline Partners LP owned about 0.98% of Upstream Bio at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new position in Upstream Bio during the fourth quarter valued at $25,000. US Bancorp DE purchased a new position in Upstream Bio during the fourth quarter valued at $27,000. Legal & General Group Plc purchased a new position in Upstream Bio during the fourth quarter valued at $28,000. Summit Investment Advisors Inc. purchased a new position in Upstream Bio during the fourth quarter valued at $30,000. Finally, Tower Research Capital LLC TRC purchased a new position in Upstream Bio during the fourth quarter valued at $47,000.
Upstream Bio Stock Performance
NASDAQ UPB remained flat at $9.62 on Wednesday. The company had a trading volume of 132,848 shares, compared to its average volume of 328,235. The business has a 50-day simple moving average of $8.08 and a 200 day simple moving average of $12.13. Upstream Bio, Inc. has a 12 month low of $5.14 and a 12 month high of $29.46.
Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.71 million. On average, sell-side analysts forecast that Upstream Bio, Inc. will post -4.3 EPS for the current year.
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
